Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2021 | Liquid biopsy vs traditional pathological approaches

Heinz Josef Lenz, MD, FACP, University of Southern California (USC), Los Angeles, CA, compares liquid biopsy to traditional clinical and pathological diagnosis technologies, such as tissue biopsy. A key advantage for liquid biopsy is that the method is highly suitable for addressing tumor heterogeneity, while a key disadvantage is that liquid biopsy can be limited in terms of the panel of genes that can be tested. Prof. Lenz highlights the range of new liquid biopsy technologies on the horizon. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.

Disclosures

Lectures/Advisory Boards: Bayer, Merck, Merck KG, BMS, Roche, Amgen, G1 Therapeutics, Jazz Therapeutics, Oncocyte, Fulgent.